title: Engineered T cells can fight malignant T cells.
abstract: In this issue of Blood, Mamonkin and colleagues report genetically engineered T cells with specificity for the lineage marker CD5 selectively kill T-lymphoma but not normal T cells, although both express the CD5 target antigen.
authors: UNIVERSITY COLLEGE LONDON.
authors: Hans J
authors: HJ
authors: Stauss
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D018956:CD5 Antigens / Q000276:immunology*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; D018956:CD5 Antigens; D011948:Receptors, Antigen, T-Cell